Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer

por Allevi, G, Strina, C, Andreis, D, Zanoni, V, Bazzola, L, Bonardi, S, Foroni, C, Milani, M, Cappelletti, M R, Gussago, F, Aguggini, S, Giardini, R, Martinotti, M, Fox, S B, Harris, A L, Bottini, A, Berruti, A, Generali, D
Publicado 2013

1672MO "DOMONCOVID PROJECT": A homecare model for cancer patients during COVID-19

por Ratti, M., Grizzi, G., Bonomi, M., Marchi, R., Negri, F., Perrucci, B., Giganti, M.O., Panni, S., Donati, G., Donini, M., Foroni, C., Gobbi, A., Barbin, F., Gerevini, F., Curti, A., Ferrari, B., Saleri, J., Passalacqua, R.
Publicado 2020

Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer

por Bazzola, L, Foroni, C, Andreis, D, Zanoni, V, R Cappelletti, M, Allevi, G, Aguggini, S, Strina, C, Milani, M, Venturini, S, Ferrozzi, F, Giardini, R, Bertoni, R, Turley, H, Gatter, K, Petronini, P G, Fox, S B, Harris, A L, Martinotti, M, Berruti, A, Bottini, A, Reynolds, A R, Generali, D
Publicado 2015